Read by QxMD icon Read


Biplab Pal, Krishna Murti, Niyamat Ali Siddiqui, Pradeep Das, Chandra Shekhar Lal, Rajendra Babu, Manoj Kumar Rastogi, Krishna Pandey
BACKGROUND: Post kala-azar dermal leishmaniasis (PKDL) is a dermatological disorder caused by protozoal parasite Leishmania donovani. PKDL cases are thought to be a reservoir of parasites and may increase cases of visceral leishmaniasis. The disease is not life threatening but cosmetic disfigurement associated with it may impair the patients' quality of life. This study aimed to assess the health related quality of life in patients with post kalaazar dermal leishmanasis for the first time...
July 24, 2017: Health and Quality of Life Outcomes
Gisele Moledo de Vasconcelos, Fernanda Azevedo-Silva, Luiz Claudio Dos Santos Thuler, Eugênia Terra Granado Pina, Celeste S F Souza, Katia Calabrese, Maria S Pombo-de-Oliveira
OBJECTIVE: This study investigated the co-existence of Leishmania chagasi infection and childhood leukemia in patients naïve to treatment; this has serious clinical and epidemiological implications. METHODS: The seroprevalence of L. chagasi antibodies prior to any treatment was investigated in children with clinical features of acute leukemia. Serological tests were performed in 470 samples drawn from under 14-year-old children from different regions of Brazil with clinical suspicion of acute leukemia...
September 2014: Revista Brasileira de Hematologia e Hemoterapia
F Javier Pérez-Victoria, María P Sánchez-Cañete, Karin Seifert, Simon L Croft, Shyam Sundar, Santiago Castanys, Francisco Gamarro
Miltefosine (hexadecylphosphocholine, MIL), registered as Impavido((R)), has become the first oral drug for the treatment of visceral and cutaneous leishmanasis. MIL is a simple molecule, very stable, relatively safe and highly efficient in clinical trials. However, MIL requires a long treatment course (28 days) and has a long half-life (around 150h), which might accelerate the emergence of drug resistance in case of inadequate use. The mechanisms of MIL resistance have been studied in vitro with experimental resistant lines...
February 2006: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
M Omidian, M A Mapar
Cutaneous leishmanasis (CL) may present with unusual clinical variants such as acute paronychial, annular, palmoplantar, zosteriform, erysipeloid, and sporotrichoid. The zosteriform variant has rarely been reported. Unusual lesions may be morphologically attributed to an altered host response or owing to an atypical strain of parasites in these lesions. We report a patient with CL in a multidermatomal pattern on the back and buttock of a man in Khozestan province in the south of Iran. To our knowledge, this is the first reported case of multidermatomal zosteriform CL...
January 2006: Indian Journal of Dermatology, Venereology and Leprology
Rachna Mittal, Pran N Behl, Govind Srivastava
Post-kala-azar dermal leishmaniasis (PKDL) as the name suggests, develops usually after 1-2 years of treated kala azar (KA).1 Infrequently, cases may be seen later than 2 years. A case of PKDL occurring after 10 years of treated KA is herein reported. Such a long disease-free interval may be forgotten by the patient, and if not carefully elicited in the history, the diagnosis of PKDL may be missed.
December 2002: International Journal of Dermatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"